AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02383069 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention Group
Description: Aerobic training
Study NCT02383069 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Chest physiotherapy: Flutter and muscle stretching
Study NCT00448214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM150
Description: Oral
Study NCT00448214 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: warfarin
Description: Oral
Study NCT01239394 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ofatumumab
Description: Weekly infusion for 8 weeks
Study NCT01853475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PQP tablets 1440mg
Description: Piperaquine phosphate tablets 1440mg
Study NCT01853475 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PQP tablets 1440mg
Description: Piperaquine phosphate tablets 1440mg
Study NCT01853475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OZ439+TPGS 800mg
Description: OZ439+TPGS prototype formulation 800mg
Study NCT01853475 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OZ439 PIB 800mg
Description: OZ439 Powder in Bottle Aqueous Solution 800mg
Study NCT01770977 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Light-emitting diode therapy
Study NCT01770977 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo light-emitting diode therapy
Study NCT02619903 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dental cleaning
Description: Dental scaling and cleaning to remove dental plaque as well as removing the tongue biofilm.
Study NCT02649738 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Corneal tissue inlay
Description: A mid-stomal pocket will be made into the cornea with a femtosecond laser (Intralase). A small disc of preserved corneal tissue will then be placed into the pocket
Study NCT03342989 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speed of Processing Training
Description: This intervention is based on computer-administered tasks that are used to evaluate Useful Field of View test, which measures discrimination between visually presented stimuli in the presence of distractors
Study NCT03342989 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Internet-Based Contact Control
Description: This intervention provides social contact and mentally stimulating activities that do not target speed of processing
Study NCT02291939 — intervention group
Intervention type: PROCEDURE
Intervention: Parotidectomy
Description: Surgical Intervention with the FMwand Surgical System
Study NCT02766777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lubiprostone
Description: 12 or 24 mcg soft capsules for oral administration.
Study NCT01911390 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Bean powder
Description: Archer Daniels Midland (ADM) Edible Bean Specialties, Inc. will supply cooked navy bean powders.
Study NCT00922870 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cascade
Description: Cascade treatment over 48h
Study NCT00922870 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Description: Standard therapy
Study NCT00799084 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse
Description: Receives 6 telephone calls over 8 weeks from an oncology nurse to assist with symptom management
Study NCT00799084 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AVR
Description: Receives 6 telephone calls over 8 weeks from an programmed automated telephone system to assist with symptom management
Study NCT01223404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants are administered a placebo patch and a placebo capsule
Study NCT01911390 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Rice bran
Description: USDA (Beaumont, TX) provided rice bran for meals that was polished from U.S. rice mills using U.S. grown rice varieties.
Study NCT01911390 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control arm
Description: No bean or rice bran additive in smoothie or muffin.
Study NCT01911390 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Bean powder and rice bran
Description: Archer Daniels Midland (ADM) Edible Bean Specialties, Inc. will supply cooked navy bean powders. USDA (Beaumont, TX) provided rice bran for meals that was polished from U.S. rice mills using U.S. grown rice varieties.
Study NCT03856983 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Point light display
Description: Experimental group who will do usual rehabilitation and visualization of point-light human actions
Study NCT01223404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: Participants are administered a nicotine patch (7 mg/24 hrs) and a placebo capsule
Study NCT02182050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120 ES low dose
Study NCT02182050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120 ES high dose
Study NCT02182050 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to BIBF 1120 ES
Study NCT03217695 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Yoga Arm
Study NCT04694170 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: additional therapy
Description: Using conventional physiotherapy together with additional yoga exercising and regimen restriction acc to TCM.
Study NCT04694170 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional physiotherapy
Description: Using conventional physiotherapy only.
Study NCT01223404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mecamylamine
Description: Participants are administered a placebo patch and a capsule containing 7.5 mg of mecamylamine
Study NCT04694170 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional physiotherapy
Description: Using conventional physiotherapy only.
Study NCT00941070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triapine
Description: Given IV
Study NCT00941070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV
Study NCT00941070 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: external beam radiation therapy
Description: Undergo pelvic external beam radiation therapy
Study NCT00941070 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT00941070 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT00941070 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fludeoxyglucose F 18
Description: Undergo FDG-PET/CT
Study NCT00941070 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography
Description: Undergo FDG-PET/CT
Study NCT00941070 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computed tomography
Description: Undergo FDG-PET/CT
Study NCT01279928 — intervention group
Intervention type: PROCEDURE
Intervention: Video Nailfold Capillaroscopy
Description: Single session of video Nailfold Capillaroscopy wit KKK technology
Study NCT00362947 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LMWH parnaparin subcutaneously
Study NCT00362947 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LMWH parnaparin subcutaneously
Study NCT02467361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBI608
Description: Patients in this trial will receive BBI608 at assigned dose-levels according to the study arm the patient is enrolled into. BBI608 Dose Level 1: 240 mg twice daily, Dose Level 2: 480 mg twice daily. The assigned dose of BBI608 will be administered twice daily with approximately 12 hours between doses.
Study NCT01279928 — intervention group
Intervention type: DEVICE
Intervention: Ambulatory 24 hr Blood Pressure Monitoring
Description: 24 hr upper arm cuff measurement of Blood Pressure
Study NCT01279928 — intervention group
Intervention type: PROCEDURE
Intervention: Fundoscopy of eyes
Description: examination of microvascular health of eye with the use of opthalmoscope
Study NCT01279928 — intervention group
Intervention type: PROCEDURE
Intervention: Laser Doppler Flowmetry
Description: Examination of vascular flow
Study NCT03174431 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continence Pessary
Description: Continence pessaries are inexpensive, reusable intravaginal devices made of flexible silicon that provide support to the urethra to prevent urinary leakage. Continence pessaries are fitted by trained clinicians in the office and managed by patients or their provider.
Study NCT03174431 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Poise Impressa (Disposable Intravaginal Device)
Description: In 2014, the FDA approved an over-the-counter disposable intravaginal device as another nonsurgical treatment for SUI. This device is comprised of 4 support poles covered in a non-absorbable nylon mesh that is deployed using an intravaginal applicator.
Study NCT02467361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab 3 mg/kg is administered intravenously over 90 minutes every 21 days for a total of 4 doses.
Study NCT02467361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 3 mg/kg is administered as an intravenous infusion over 60 minutes every 14 days.
Study NCT02467361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 2 mg/kg is administered as an intravenous infusion over 30 minutes once every 21 days.
Study NCT02097303 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Concurrent use of Radium Ra 223 dichloride and Abiraterone Acetate plus Prednisone
Description: Radium Ra 223 dichloride - A targeted alpha particle-emitting pharmaceutical (a radiopharmaceutical drug) is a ready-to-use solution for intravenous injection containing the drug substance radium dichloride. The active moiety is the alpha particle emitting nuclide Ra-223, present as a divalent cation (223Ra2+) and Abiraterone Acetate - A CYP17 inhibitor, indicated in combination with prednisone for the treatment of subjects with metastatic castration-resistant prostate cancer. Administration of Abiraterone Acetate may result in mineralocorticoid-related adverse events (AEs), due to CYP17 inhibition. Therefore, Abiraterone Acetate is administered in combination with Prednisone to reduce the frequency of these AEs.
Study NCT02463045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TOP1288
Study NCT02049736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telbivudine
Study NCT00965107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiopental
Description: Thiopental given as a bolus dose of 2,5 mg/kg.
Study NCT04162379 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Oral tablet
Description: Patients will be allocated as single group and will take oral prednisolone (sulopride10 mg) single dose every two days for 4 successive weeks then the next two weeks as washout period (stop dosing gradually by taking 5 mgs for 3 successive dosing every 2nd day over a week, then stop the oral steroid drug totally over the 2nd week of the washout period. The second period of the study will start by taking the oral prednisolone (sulopride10 mg) every fourth day for the next 4 weeks after which the patient will get another washout two weeks period (stop dosing gradually 5 mg for 3 successive dosing every 4th day then stop the drug totally).
Study NCT00965107 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol given as a bolus dose of 1 mg/kg.
Study NCT04441177 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PlayStation®VR training
Description: Participants in the study group receive conventional rehabilitation therapy over 50 minutes on weekdays and 7 sessions (flexible schedule in different day) of PlayStation®VR of 20 minutes each in the main 16-day study period.
Study NCT04481698 — intervention group
Intervention type: OTHER
Intervention: Mesoglycan
Description: Prisma® 30 mg 2 vials i.m./day for the first 5 post-operative days and then Prisma® 50 mg 1 oral tablet twice/day for an additional 30 days
Study NCT03787342 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Double Flap Incision
Description: A full-thickness crestal incision will be made over the edentulous ridge, and then one partial-thickness vertical incision will be made on the buccal side. A partial-thickness flap will be raised first to separate the mucosal layer from the overlying periosteum. Subsequently, the periosteal layer will be elevated to expose the underlying alveolar process. Xenograft and Ti-mesh will be used to augment the defective site then periosteal flap will be sutured first, with periosteal sutures securing the regenerative site. Then the mucosal flap will be closed.
Study NCT03787342 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified Periosteal Releasing Incision
Description: A full-thickness muco-periosteal flap is reflected on the buccal side (crestal incision and two vertical releasing incisions). Near the base of mucoperiosteal flap, the periosteum is incised less than 0.5mm in depth, creating two segments, coronal segment and apical segment, of the periosteal flap. The shallow incision helps in preventing damage to the submucosal layer. The flap is pulled with a pair of periodontal forceps laterally. Subsequently, the lateral stretching of the coronal segment of the flap is performed by applying pressure using the blunt face of scalpel blade with sweeping motion to allow flap advancement.
Study NCT03787342 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronally Advanced Lingual Flap
Description: A full-thickness crestal incision will be performed in the keratinized tissue from the distal surface of the more distal tooth to the retromolar pad. The flap design will be continued intrasulcularly on both vestibular and lingual sides of the mesial portion of the flap, buccally, it will be finished with a vertical releasing incision. On the lingual side, a full-thickness mucoperiosteal flap will be elevated until reaching the mylohyoid line. Then, using a blunt instrument it will be localized a connective tissue band continuing with the epimysium of the mylohyoid muscle. The blunt instrument will be inserted below this connective band, and, with gentle traction in the coronal direction, this muscular insertion will be detached from the lingual flap.
Study NCT03787342 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Periosteal releasing incision
Study NCT02299947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Haemocomplettan P
Study NCT02299947 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00299494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inotuzumab ozogamicin
Description: IV, 1.8 mg/m2, q4w
Study NCT00299494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: rituximab 375 mg/m\^2 via IV infusion on Day 1
Study NCT04921891 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Infraclavicular nerve block
Description: The investigators performed an infraclavicular nerve block to the operated arm group to provide anesthesia.
Study NCT04921891 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Without nerve block
Description: The upper extremity without block was assigned as the control group, and a comparison was made between the two upper extremities.
Study NCT00383539 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Split-virion influenza vaccine
Description: Vaccine Lot 1
Study NCT00383539 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Split-virion influenza vaccine
Description: Vaccine Lot 2
Study NCT00383539 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Split-virion influenza vaccine
Description: Vaccine Lot 3
Study NCT00383539 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactivated Split-virion influenza vaccine
Description: Control Vaccine
Study NCT05520853 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT combined with PD-1 inhibitors and thoracic hyperthermia
Description: At least one lesion (primary or metastatic) was selected for SBRT treatment, and the radiotherapy dose of each lesion was 32Gy/4Fx. SBRT was combined with thoracic hyperthermia from the first fraction, and hyperthermia was performed 6 times, twice a week. PD-1 inhibitor was used on the second day after the completion of SBRT. The PD-1 inhibitor was administered at a dose of 200mg every time, every 3 weeks for 2 years (35 times total), or until the investigators deem that the patient need to discontinue the drug because of treatment-related toxicity or disease progression.
Study NCT03969134 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ChAd63-KH
Description: The vaccine will be injected intramuscularly into the arm.
Study NCT03969134 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo will be injected intramuscularly into the arm.
Study NCT00571181 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed-loop system
Description: Automatic delivery of propofol and remifentanil
Study NCT00571181 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TCI (Infusion Toolbox)
Description: TCI administration of propofol and remifentanil
Study NCT02760095 — intervention group
Intervention type: DRUG
Intervention: 3 mg zinc sulfate supplement
Study NCT02760095 — intervention group
Intervention type: DRUG
Intervention: 0.5 mg of 13C10-retinyl-acetate
Study NCT01075295 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioural Intervention for the Prevention of Weight Gain
Description: The intervention consists of four steps:~* STEP 1 (Watchful Waiting): Measurement of body weight and Waist Circumference at the start (1 visit). Subjects that have a weight gain greater then or equal to 2% of their baseline weight will progress to Step 2~* STEP 2 (Self monitoring): Self-monitoring of daily weight, daily food intake \& physical activity (1 visit) Subjects that have a weight gain greater then or equal to 2% (from STEP 2) will progress to Step 3~* STEP 3 (Nutrition \& Exercise Counseling): Counseling for nutrition and physical activity (4 visits; 2 in-clinic, 2 telephone) Subjects that have a weight gain greater then or equal to 2% (from STEP 3) will progress to Step 4~* STEP 4 (Intensive): Intensive behavioral training geared towards reducing caloric intake (4 in-clinic visits)
Study NCT01075295 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TAU
Description: Treatment as provided by individuals' existing healthcare providers
Study NCT02964533 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: thunder-fire moxibustion therapy
Description: burn moxa stick and heat shenque acupoint
Study NCT02964533 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: common moxa-stick moxibustion
Description: burn moxa stick and heat shenque acupoint
Study NCT02440425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab: 200 mg, every (Q) 3 weeks, via intravenous (IV) infusion, until progression or toxicity (or up to 24 months). The first cycle will begin on day 8.
Study NCT02440425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel: 80 mg/m\^2, Q week for 3 weeks, via IV infusion, until progression or toxicity (or complete response if at least 6 cycles, at the discretion of the investigator and participant). Cycle 1 will have an extra lead in week (4 weeks total) with Paclitaxel only on week 1.
Study NCT02517762 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Study NCT00214019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: salmeterol
Description: salmeterol diskus 50 mcg twice per day
Study NCT00214019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone
Description: placebo diskus, fluticasone MDI 88 mcg twice per day
Study NCT00214019 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo diskus
Study NCT03880136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTP-543
Description: Once daily dosing
Study NCT03921099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid
Description: ascorbic acid is an antioxidant that is expected to prevent nephrotoxicty induced by Vancomycin.
Study NCT02092623 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Transvaginal posterior mesh
Description: A trocar-free fixation system with low-weight mesh
Study NCT01567631 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intrahepatic Glisson's approach
Description: Forty patients with liver disease were selected and divided into intrahepatic Glission's group as described in the detailed description.Total laparoscopic hepatectomy with intrahepatic Glisson's approach were performed. Operation began with division of liver ligaments, liver mobilization, followed by intrahepatic access to the Glissonian pedicle (containing arterial, portal, and bile duct branches ). A endoscopic stapler devices was used for Glissonian pedicle cutting and suture. Liver parenchyma was divided by harmonic scalpel combined with vascular stapler. The specimen was extracted through suprapubic incision.